Apogee Therapeutics

About Apogee Therapeutics

Apogee Therapeutics is dedicated to developing best-in-class therapies for immunological and inflammatory disorders. Their mission is to reshape the standard of care for these conditions by exploring treatment options that work better and longer, refusing to settle for 'good enough'. They aim to improve the lives of patients with inflammatory and immune (I&I) diseases through innovative scientific approaches and differentiated therapies.

Products & Services

APG777:A novel antibody therapeutic targeting IL-13, currently in Phase 2 for Atopic Dermatitis and Phase 1 for Asthma and Eosinophilic Esophagitis.

APG279 (APG777 + APG990):A combination therapy targeting IL-13 and OX40L, currently in Phase 1 for Atopic Dermatitis.

Specialties

Immunological Disorders Inflammatory Diseases Antibody Therapeutics Dermatology (Atopic Dermatitis) Respiratory Conditions (Asthma) Gastroenterology (Eosinophilic Esophagitis)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 345000000 MR: - FA: $345 million FAN: 345000000	D: 2025-10-10 FD: 2025-10-10	5 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2025-10-08 FD: 2025-10-08	5 investors
3	RT: Public Offering T: - FT: Public Offering	A: 483000000 MR: - FA: approximately $483.0 million FAN: 483000000	D: 2024-03-12 FD: 2024-03-12	5 investors
4	RT: Public Offering T: - FT: Public Offering	A: 420000000 MR: - FA: $420 million FAN: 420000000	D: 2024-03-07 FD: 2024-03-07	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: approximately $350.0 million FAN: 350000000	D: 2024-03-05 FD: 2024-03-05	5 investors
6	RT: IPO T: - FT: IPO	A: 345000000 MR: - FA: approximately $345 million FAN: 345000000	D: 2023-07-18 FD: 2023-07-18	5 investors
7	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 300000000 MR: - FA: $300 million FAN: 300000000	D: 2023-07-13 FD: 2023-07-13	5 investors

Public Offering Latest

2025-10-10

$345.0M

5 investors (Pro only)

Underwritten Public Offering 2025-10-08

$300.0M

Public Offering 2024-03-12

$483.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael Henderson

Chief Executive Officer

LinkedIn (Pro only)

C

Carl Dambkowski

Chief Medical Officer

LinkedIn (Pro only)

J

Jane Pritchett Henderson

Chief Financial Officer

LinkedIn (Pro only)

R

Rebecca Dabora

Chief Development Officer

M

Matt Batters

Chief Legal Officer

J

Jeff Hartness

Chief Commercial Officer

View 13 more team members with Pro

Unlock Full Team Directory

Recent News